Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.44 |
| ▸ | OGFRL1 | Q5TC84 | 4/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700299 | 0.94 | OPRM1 (0.47) | OPRM1OGFRL1OPRL1LMNAMEN1 | |
| SCHEMBL700742 | 0.93 | OPRM1 (0.44) | OPRM1OGFRL1OPRL1LMNATP53 | |
| SCHEMBL700318 | 0.91 | OPRM1 (0.45) | OPRM1OGFRL1OPRL1MEN1KMT2A | |
| SCHEMBL2328906 | 0.89 | OPRM1 (0.45) | OPRM1OGFRL1OPRL1LMNATP53 | |
| SCHEMBL700360 | 0.89 | OPRM1 (0.44) | OPRM1OGFRL1OPRL1LMNATP53 | |
| SCHEMBL698242 | 0.88 | OPRM1 (0.46) | OPRM1OGFRL1OPRL1MEN1KMT2A | |
| SCHEMBL698513 | 0.87 | OPRM1 (0.46) | OPRM1OGFRL1OPRL1TRPV1CDK4 | |
| SCHEMBL701237 | 0.87 | OPRM1 (0.46) | OPRM1OGFRL1OPRL1LMNATP53 | |
| SCHEMBL699422 | 0.87 | OPRM1 (0.45) | OPRM1OGFRL1OPRL1TRPV1CDK4 | |
| SCHEMBL700109 | 0.86 | OPRM1 (0.45) | OPRM1OGFRL1OPRL1LMNATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124788-B2 | Spirocyclic cyclohexane compounds with analgesic activity | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | claimed |
| EP-2010531-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES WITH ANALGESIC PROPERTIES | GRUENENTHAL GMBH (DE) | 2011-08-17 | — | — | EP | claimed |
| US-20090111842-A1 | SPIROCYCLIC CYCLOHEXANE COMPOUNDS WITH ANALGESIC ACTIVITY | GRUENENTHAL GMBH (DE) | 2009-04-30 | — | — | US | claimed |
| US-8124788-B2 | Spirocyclic cyclohexane compounds with analgesic activity | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| EP-2010531-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES WITH ANALGESIC PROPERTIES | GRUENENTHAL GMBH (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-20090111842-A1 | SPIROCYCLIC CYCLOHEXANE COMPOUNDS WITH ANALGESIC ACTIVITY | GRUENENTHAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| EP-2010531-A1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVE WITH ANALGESIC PROPERTIES | Grünenthal GmbH (DE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007124903-A1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVE WITH ANALGESIC PROPERTIES | Grünenthal GmbH (DE) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111842-A1 | SPIROCYCLIC CYCLOHEXANE COMPOUNDS WITH ANALGESIC ACTIVITY | OPRK1, OPRL1, OPRD1 | OPRM1 9/4885OGFRL1 163/4885OPRL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.